Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Martin Lehr Biography and Net Worth

CEO of Context Therapeutics

Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecular, an antibody discovery company. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. At Osage, Martin focused on early stage oncology and rare disease opportunities. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis. In addition to his role at Context, Martin is a Director of BioBreak, a biotech executive peer group with over 2,500 active members across the United States. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.

+ LinkedIn

What is Martin A. Lehr's net worth?: The estimated net worth of Martin A. Lehr is at least $162,895.02 as of February 21st, 2023. Mr. Lehr owns 159,701 shares of Context Therapeutics stock worth more than $162,895 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Lehr may own. Additionally, Mr. Lehr receives an annual salary of $674,080.00 as CEO at Context Therapeutics. Learn More about Martin A. Lehr's net worth.
How old is Martin A. Lehr?: Mr. Lehr is currently 40 years old. There are 2 older executives and no younger executives at Context Therapeutics. Learn More on Martin A. Lehr's age.
What is Martin A. Lehr's salary?: As the CEO of Context Therapeutics Inc., Mr. Lehr earns $674,080.00 per year. Learn More on Martin A. Lehr's salary.
How do I contact Martin A. Lehr?: The corporate mailing address for Mr. Lehr and other Context Therapeutics executives is 3675 Market Street, Philadelphia, Pennsylvania 19104. Context Therapeutics can also be reached via phone at 267-225-7416 and via email at [email protected]. Learn More on Martin A. Lehr's contact information.
Has Martin A. Lehr been buying or selling shares of Context Therapeutics?: Martin A. Lehr has not been actively trading shares of Context Therapeutics within the last three months. Most recently, on Tuesday, February 21st, Martin A. Lehr bought 5,823 shares of Context Therapeutics stock. The stock was acquired at an average cost of $0.84 per share, with a total value of $4,891.32. Following the completion of the transaction, the chief executive officer now directly owns 159,701 shares of the company's stock, valued at $134,148.84. Learn More on Martin A. Lehr's trading history.
Who are Context Therapeutics' active insiders?: Context Therapeutics' insider roster includes Martin Lehr (CEO), and Alex Levit (Insider). Learn More on Context Therapeutics' active insiders.

Martin A. Lehr Insider Trading History at Context Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/21/2023	Buy	5,823	$0.84	$4,891.32	159,701
2/13/2023	Buy	5,606	$0.87	$4,877.22	153,878
2/6/2023	Buy	5,040	$0.97	$4,888.80	148,272
1/30/2023	Buy	7,027	$0.70	$4,918.90	143,232
1/23/2023	Buy	6,839	$0.72	$4,924.08	136,205
1/17/2023	Buy	6,783	$0.74	$5,019.42	129,366
8/19/2022	Buy	13,000	$1.85	$24,050.00	102,583
12/16/2021	Buy	13,000	$3.22	$41,860.00
10/22/2021	Buy	10,000	$5.00	$50,000.00

Martin A. Lehr Buying and Selling Activity at Context Therapeutics

Context Therapeutics Company Overview

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $1.02

$0.96

$1.11

50 Day Range

MA: $1.78

$1.02

$2.35

2 Week Range

Now: $1.02

$0.89

$2.75

Volume

339,733 shs

Average Volume

299,858 shs

Market Capitalization

$76.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

Missed Nvidia? Buy Elon Musk’s “Silent Partner”

From Brownstone Research | Ad